Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berberine or caffeic acid for minimal hepatic encephalopathy in cirrhosis
ChiCTR2100052806Phase 3Not yet recruiting
- Sponsor
- Huadong Hospital, Fudan University
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of berberine and caffeic acid in hepatic encephalopathy (HE) (3 arms), sponsored by Huadong Hospital, Fudan University. Primary endpoints: Psychometric Hepatic Encephalopathy Score, Stroop test and 1 more. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
berberinecaffeic acid
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on ChiCTR2100052806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052806.